Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.44 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | PYGL | P06737 | 1/20 | 0.43 |
| ▸ | PYGM | P11217 | 1/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | GRM5 | P41594 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.42 |
| ▸ | KDM5A | P29375 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | KDM6B | O15054 | 1/20 | 0.41 |
| ▸ | KDM5C | P41229 | 1/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556944 | 0.85 | GRM5 (0.60) | ALDH1A1GRM4GRM5GABRG2GABRB3 | |
| SCHEMBL3077434 | 0.83 | KDM4E (0.48) | ALDH1A1GRM5HCRTR1HCRTR2KDM4E | |
| SCHEMBL1853358 | 0.81 | ALDH1A1 (0.46) | ALDH1A1GRM4EGLN2PYGLPYGM | |
| SCHEMBL3711888 | 0.81 | ACACB (0.60) | ACACBALDH1A1ARGRM5MAPK1 | |
| SCHEMBL22637041 | 0.80 | GRM4 (0.38) | ACACBGRM4PYGLPYGMLRRK2 | |
| SCHEMBL17546406 | 0.80 | LRRK2 (0.48) | GRM4EGLN2PYGLPYGMLRRK2 | |
| SCHEMBL3709785 | 0.80 | ACACB (0.53) | ACACBALDH1A1ARMAPK1KDM4E | |
| SCHEMBL3710270 | 0.80 | ACACB (0.59) | ACACBALDH1A1KDM4EKDM6BKDM5C | |
| SCHEMBL31044510 | 0.80 | ACACB (0.53) | ACACBALDH1A1ARMAPK1KDM4E | |
| SCHEMBL19249060 | 0.80 | GRM5 (0.50) | ACACBGRM4EGLN2PYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3704113-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2020-09-09 | — | — | EP | disclosed |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-08-04 | — | — | US | disclosed |
| CN-111295382-A | Bridged bicyclic compounds as modulators of farnesoid X receptors | 百时美施贵宝公司 | 2020-06-16 | — | — | CN | disclosed |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2019-05-02 | — | — | US | disclosed |
| US-8778919-B2 | Cyclic anilino—pyridinotriazines | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| EP-2050446-B1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2014-05-07 | — | — | EP | disclosed |
| US-7973078-B2 | Sulfonamide compound or salt thereof | ASTELLAS PHARMA INC. (JP) | 2011-07-05 | — | — | US | disclosed |
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-09-02 | — | — | US | disclosed |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-12-17 | — | — | US | disclosed |
| EP-1904461-B1 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-08-12 | — | — | EP | disclosed |
| EP-2050446-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-04-22 | — | — | EP | disclosed |
| EP-1904461-A2 | CYCLIC ANILINOPYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007003525-A2 | CYCLIC ANILINO-PYRIDINOTRIAZINES AS GSK-3 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222574-A1 | CYCLIC ANILINO - PYRIDINOTRIAZINES | NR4A1, NR4A2, NR5A2 | ACACB 4771/4885ALDH1A1 2052/4885GRM4 296/4885 |
| US-20090312328-A1 | SULFONAMIDE COMPOUND OR SALT THEREOF | PTGER1, CYSLTR1, PTGER2 | ACACB 4182/4885ALDH1A1 511/4885GRM4 1400/4885 |
| US-20190127358-A1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | NR1H4, FXR1, NR1H2 | ACACB 530/4885ALDH1A1 2602/4885GRM4 579/4885 |
| US-10730863-B2 | Bridged bicyclic compounds as farnesoid X receptor modulators | NR1H4, FXR1, NR1H2 | ACACB 530/4885ALDH1A1 2602/4885GRM4 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.